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Genome-wide association studies (GWAS) have so far identified 25 loci associated with glioma risk, 
with most showing specificity for either glioblastoma (GBM) or non-GBM tumors. The majority of 
these GWAS susceptibility variants reside in non-coding regions and the causal genes underlying 
the associations are largely unknown. Here we performed a transcriptome-wide association study 
to search for novel risk loci and candidate causal genes at known GWAS loci using Genotype-Tissue 
Expression Project (GTEx) data to predict cis-predicted gene expression in relation to GBM and 
non-GBM risk in conjunction with GWAS summary statistics on 12,488 glioma cases (6,183 GBM, 
5,820 non-GBM) and 18,169 controls. Imposing a Bonferroni-corrected significance level of 
P<5.69×10-6, we identified 31 genes, including GALNT6 at 12q13.33, as a candidate novel risk locus 
for GBM (mean Z=4.43, P=5.68×10-6). GALNT6 resides at least 55 Mb away from any previously-
identified glioma risk variant, while all other 30 significantly-associated genes were located within 
1 Mb of known GWAS-identified loci and were not significant after conditioning on the known 
GWAS-identified variants. These data identify a novel locus (GALNT6 at 12q13.33) and 30 genes at 
12 known glioma risk loci associated with glioma risk, providing further insights into glioma 
tumorigenesis. 
 
Significance: Our study identifies new genes associated with glioma risk, increasing our 












Diffuse gliomas are the most common malignant primary brain tumor affecting adults1. Gliomas can 
be broadly classified into glioblastoma (GBM) and low-grade non-GBM tumors. Gliomas typically 
have a poor prognosis irrespective of medical care, with the most common form, glioblastoma 
multiforme (GBM), having a median overall survival of only 10–15 months1. While the glioma 
subtypes have distinct molecular profiles resulting from different aetiological pathways, no 
environmental exposures have consistently been linked to risk except for ionizing radiation, which 
only accounts for a very small number of cases1. Inherited genetic factors do, however play an 
important role in the aetiology of glioma and genome-wide association studies (GWAS) have so far 
identified common variants at 25 loci influencing disease risk2. Perhaps not surprisingly given 
differences in the molecular profile of GBM and non-GBM tumors, subtype-specific associations are 
shown for a number of the risk variants3,4. Collectively, the known risk loci only account for around a 
third of the familial risk of both GBM and non-GBM glioma2 indicating that additional susceptibility 
variants remain to be identified. 
 
Many of the GWAS risk variants are likely to have a small effect size, and thus are difficult to identify 
in individual SNP-based GWAS, even with large sample numbers2. Applying gene-based approaches 
that aggregate the effects of multiple variants into a single testing unit is thus attractive and offers 
the prospect of increasing study power. Most GWAS risk variants reside in non-coding regions and 
are primarily located in active chromatin regions, which are highly-enriched with expression 
quantitative trait loci (eQTL)5. Hence transcriptome-wide association studies (TWAS) that 
systematically investigate the association of genetically predicted gene expression with disease risk 
offers a potentially attractive strategy to identify novel susceptibility genes for glioma6,7. 
 
Herein, we report results from a TWAS of glioma implementing the MetaXcan8 methodology to 
analyse summary statistics data from 12,488 cases and 18,169 controls of European descent. We 
identify 31 genes at 13 loci associated with glioma risk, and provide additional evidence of a 






A TWAS was undertaken using previously reported GWAS data2. Ethical approval was not sought for 
this specific project because all data came from the summary statistics from the published GWAS, 
and no individual-level data were used. 
 
GWAS data 
Glioma genotyping data were derived from the most recent meta-analysis of GWAS in glioma, which 
related > 6 million genetic variants (after imputation) to glioma, in 12,488 patients and 18,169 
controls from eight independent studies of individuals of European descent (Supplementary Table 
1). Comprehensive details of the genotyping and quality control of these GWAS have been previously 
reported2. Gliomas are heterogeneous and different tumor subtypes, defined in part by malignancy 
grade (e.g. pilocytic astrocytoma World Health Organization (WHO) grade I, diffuse ‘low-grade’ 
glioma WHO grade II, anaplastic glioma WHO grade III and glioblastoma (GBM) WHO grade IV) can 
be distinguished. For the sake of brevity we considered gliomas as being either GBM or non-GBM 
tumors. 
 
Association analysis of predicted gene expression with glioma risk 
Associations between predicted gene expression and glioma risk were examined using MetaXcan8, 
which combines GWAS and eQTL data, accounting for LD-confounded associations. Briefly, genes 
likely to be disease-causing were prioritised using S-PrediXcan which uses GWAS summary statistics 
and pre-specified weights to predict gene expression, given co-variances of SNPs. SNP weights and 
their respective covariance for 13 brain tissues (amygdala, anterior cingulate cortex, caudate basal 
ganglia, cerebellar hemisphere, cerebellum, cortex, frontal cortex, hippocampus, hypothalamus, 
nucleus accumbens basal ganglia, putamen basal ganglia, spinal cord and substantia nigra) from 80-
154 individuals were obtained from predict.db (http://predictdb.org/)8, which is based on GTEx 
version 7 eQTL data. To combine S-PrediXcan data across the different brain tissues taking into 
account tissue-tissue correlations we used S-MultiXcan. 
 
To determine if associations between genetically-predicted gene expression and glioma risk were 
influenced by variants previously identified by GWAS, we performed conditional analyses adjusting 
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for sentinel GWAS risk SNPs (Supplementary Table 3) using GCTA-COJO9,10. Adjusted output files 
were provided as the input GWAS summary statistics for S-PrediXcan analyses as above. 
For all significant genes identified by S-MultiXcan analyses we additionally considered the effect of 
the top eSNP on glioma risk. For each identified gene, the most significant eSNP for each brain tissue 
was identified from GTEx v7 “allpairs.txt.gz” files. Glioma GWAS summary statistics for the 
surrounding region were estimated after conditioning on identified significant eSNP/s using GCTA-
COJO9,10, using “—cojo-slct” and “—cojo-p 0.05” to select independent eSNPs and avoid collinearity 
in association testing. 
 
To account for multiple comparisons we first considered a simple Bonferroni-corrected P-value 
threshold of 3.45×10-6 (i.e. 0.05/14,486 genes) to determine a statistically significant association. 
This is, however, inherently conservative because expression of genes can be correlated. To identify 
highly correlated genes we performed a weighted correlation network analysis using WGCNA 
v1.6311. Plots of soft threshold against the scale-free topology model fit were used to determine the 
threshold preserving 90% of topology (Supplementary Table 5). Dendograms and heatmaps were 
generated to visualise co-expression of genes. The number of clusters reflects the number of 
independent gene sets. We examined the comparability of gene clustering across brain tissues by 
dendogram Z-values; with a Z-value of 5-10 corresponding to moderate preservation and a Z-value 
>10 being indicative of strong preservation (Supplementary Figure 5, Supplementary Table 6). To 
estimate the number of independently expressed genes per brain tissue we assessed gene-gene 
adjacency (i.e. correlation) values. Significantly correlated gene-gene pairs were identified as 
those with adjacency values greater than three standard deviations from the mean. Removing at 
random one correlated gene from each pair left an estimate of the number of “independent 
genes” (Supplementary Table 5). The median number of independent genes was 8,781 which 
defined the TWAS Bonferroni-correct threshold as P < 5.69x10-6. 
 
S-PrediXcan analyses were additionally carried out on 922 whole-blood samples from Depression 
Genes and Networks (DGN), in order to compare associations at genes identified as significant from 
S-MultiXcan analyses in brain, and aid interpretation of potential tissue-specific and generic eQTL 




Identified genes were annotated by their potential presence in the v87 COSMIC cancer gene census 
(https://cancer.sanger.ac.uk/cosmic/) as well as their potential overlap with copy number gains and 
losses as annotated in CosmicCompleteCNA.tsv.gz. 
 
 
Statistical power for association tests 
To assess the power of our TWAS to identify associations we performed a simulation analysis 
adopting a similar strategy to Wu et al., 20186. We set the number of cases and controls as 12,488 
(6,183 GBM, 5,820 non-GBM) and 18,169, respectively. Glioma prevalence estimates were obtained 
from CBTRUS 201712, assuming an overall incidence of primary brain and CNS tumors to be 22.6 per 
100,000, of which 27% are gliomas and 56% of gliomas are GBM. We generated the gene expression 
levels from the empirical distribution of gene expression levels in GTEx normalised expression 
dataset for each brain tissue. We calculated statistical power at P < 5.69 × 10−6, corresponding to the 
TWAS genome-wide significance level, according to various cis-heritability (h2) thresholds that are 
assumed to be equivalent to gene expression prediction models (R2). The results, based on 1,000 







We evaluated the association between predicted gene expression levels and glioma risk using 
MetaXcan with summary statistics for GWAS SNPs in 12,488 glioma cases and 18,169 controls. In 
view of associations for glioma being strongly subtype-specific2, we analysed TWAS results for GBM 
and non-GBM cases. Figure 1 shows Manhattan plots for respective TWAS associations. Quantile-
quantile plots of TWAS association statistics did not show evidence of systematic inflation 
(Supplementary Figure 1).  
 
In total the expression levels of 14,485 genes were tested for an association with glioma. To establish 
the threshold for assigning genomewide statistical significance taking into account correlations 
between gene expression we carried out WGCNA11 analysis to determine the number of 
independent gene sets (Supplementary Table 5). Based on an estimated number of uncorrelated 
genes of 8,781 we imposed a Bonferroni multiple-testing threshold of P < 5.69 x 10-6 to declare 
significant associations.  
 
Applying this threshold, we identified 23 genes associated with GBM, and eight with non-GBM 
glioma (Figure 1, Table 1, Supplementary Table 4, Supplementary Table 7). All identified genes but 
one were within 1Mb of previously reported glioma risk SNPs. After conditioning on the nearby 
GWAS glioma risk SNP in each case gene associations were severely abrogated, consistent with the 
TWAS associations reflecting the prevously identified GWAS associations. The exception was GALNT6 
at 12q13.13, which did not map within 1Mb of a previously identified GWAS risk SNP and was 
significantly associated with GBM. The risk allele (T) of sentinel SNP rs3782473 at 12q13.13 had an 
association P-value of 9.08x10-8 (Odds ratio 1.15, 95% confidence interval 1.09-1.21) with GBM 
(Figure 2). After conditioning on rs3782473 there were no significant TWAS associations at 12q13.13, 
consistent with the association signal defined by rs3782473 underlying the association with GALNT6 
(Supplementary Table 4). In nine out of 13 brain regions there was a significant association between 
the risk allele (T) of rs3782473 and increased expression of GALNT6 (Supplementary Figure 6). 
 
For many loci our TWAS findings broadly supports the involvement of a number of genes that have 
previously been proposed to be implicated in defining glioma risk3. Specifically, single gene 
associations were identified at 1p31.3 (JAK1), 7p11.2 (EGFR), 9p21.3 (CDKN2B) and 16q12.1 
(HEATR3). However, at a number of loci our analysis identified multiple significant genes, notably 
9 
 
5p15.33 (TERT and NKD2), 11q23.3 (PHLBD1, TREH, RPL5P30, TMEM25) and 20q13.33 (ZGPAT, 
SLC2A4RG, ARFRP1, STMN3, GMEB2, LIME1, HAR1A, OPRL1, PFMTD2, DIDO1, TCEA2). No significant 
genes were identified at nine previously reported glioma risk loci (3p14.1, 8q24.21, 10q24.33, 
10q25.2, 11q23.2, 12q12.1, 14q12, 15q24.1, 17p13.1). 
 
To explore the possibility of generic eQTL effects we considered S-PrediXcan analyses at the 31 
identified genes using 922 whole-blood samples from the Depression Genes and Networks (DGN) 
study (Supplementary Table 8). Twelve  genes were significantly associated at P<0.05 and had a 
consistent direction of effect with S-MultiXcan analyses (GBM: JAK1 at 1p31.3, TERT at 5p15.33, 
GALNT6 at 12q13.13, HEATR3 at 16q12.1, ZGPAT, ARFRP1, GMEB2, LIME1 and PCMTD2 at 20q13.33; 
non-GBM: TERT at 5p15.33, TMEM25 at 11q23.3, ZGPAT at 20q13.33), six genes were inconsistent 
(GBM: CDKN2B at 9p21.3, SLC2A4RG, STMN3, OPRL1 and TCEA2 at 20q13.33; non-GBM: PHLDB1 at 
11q23.3), four genes were not significantly associated (GBM: DIDO1 at 20q13.33, BAIAP2L2 and 
PICK1 at 22q13.1; non-GBM: SLC2A4RG at 20q13.33) and eight genes could not be assessed (GBM: 
NKD2 at 5p15.33, EGFR at 7p11.2, IL9RP3 at 16p13.3, HAR1A at 20q13.33, SLC16A8 and CTA-228A9.3 
at 22q13.1; non-GBM: TREH and RPL5P30 at 11q23.3). 
 
Following on we further investigated the relationship between the 31 genes identified as 
significantly associated with GBM or non-GBM by examining associations after adjusting for the top 
eSNP/s at each gene (Supplementary Figure 8). For most loci, association signals were abrogated 
after adjusting for the top eSNP/s, consistent with variation in expression of the identified gene 
being functional. In contrast, the association signals at 11q23.3 and 20q13.33 were only really 
affected by adjusting for multiple rather than individual gene eSNPs, raising the possibility of 
combinatorial effects. Intriguingly at 7p11.2, which is characterised by two independent risk loci 
(marked by rs75061358 and rs723527 respectively), after adjustment for the EGFR eSNPs the 
rs75061358 signal disappears, while the rs723527 signal is unaffected, perhaps indicative of an 
additional distinct as yet unidentified functional mechanism. 
 
Finally, we compared overlap of the 31 identified genes with presence in the COSMIC cancer gene 
census as an oncogene or tumor suppressor gene, as well as whether the given gene is subject to 
copy number gains and/or losses (Supplementary Table 9). Most TWAS directions of effect are 
consistent with the gene’s probable role in tumorigenesis, such as the tumor suppressor gene 
CDKN2B, whereby decreased expression is associated with increased glioma risk. However, at 7p11.2 
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increased expression of the oncogene EGFR, which is commonly upregulated in gliomas, was found 
by S-MultiXcan analyses to be negatively associated with glioma risk, perhaps indicative of different 





In this large TWAS involving 12,488 glioma cases of European ancestry, we identified genetically-
predicted expression levels in 23 genes associated with GBM, and eight with non-GBM glioma risk. 
One of these genes, GALNT6, is located at least 55 Mb away from any previously identified GWAS 
glioma variant, consistent with it representing a potential novel risk locus. All other 30 genes 
identified were located within 1 Mb of known GWAS loci, including 14 genes at three loci that had 
not previously been associated with glioma risk.  
 
Our findings provide further support study for a number of the genes previously implicated by GWAS 
whose expression influences the risk of developing glioma. These include JAK1 at 1p31.3, PHLDB1 at 
11q23.3, EGFR at 7p11.2 and HEATR3 at 16q12.1. Additionally, our TWAS implicates new genes at 
known glioma loci, including TMEM25 at 11q23.3 and NKD2 at 5p15.33 as playing a role in defining 
risk of non-GBM and GBM tumors respectively. TMEM25 has been identified as a member of the 
immunoglobulin superfamily, whose members are implicated in immune responses, growth factor 
signalling and cell adhesion13. Intriguingly, NKD2 encodes a Wnt-pathway inhibitor that is 
hypermethylated in a large proportion of GBM tumors14. The functional consequence of rs10069690 
at 5p15.33 has previously been reported to be due to the risk allele (A) creating an additional splice 
donor site in the fourth intron of TERT, resulting in expression of a dominant negative transcript 
inhibiting telomerase15. Therefore the TWAS association with TERT may not be directly due to cis-
regulatory effects but as an indirect consequence of this dominant negative effect, with a possible, 
albeit currently undetermined, effect on expression of NKD2. 
 
In addition to refining the genes underscoring previously reported GWAS associations, our TWAS 
study identified a new gene, GALNT6 at 12q13.33, a locus not previously identified as playing a role 
in GBM. The gene product of GALNT6 is polypeptide N-acetylgalactosaminyltransferase 6, which is a 
class of proteins frequently disrupted in cancers16. Of note is that GALNT6 expression regulates EGFR 
activity17. While requiring further investigation, GALNT6 and rs3782473 represent a promising new 
glioma risk locus. 
 
A large number of genes associated with glioma risk were located at 20q13.33. These include DIDO1, 
PCMTD2, HAR1A and TCEA2. HAR1A expression is reduced in GBM and has been shown to be a 
prognostic biomarker for diffuse glioma18. While DIDO1, PCMTD2 and TCEA2 have not previously 
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been shown to be associated with glioma, DIDO1 promotes cell-fate differentiation in embryonic 
stem cells19 and TCEA2 encodes transcription elongation factor A protein 2, which interacts with 
BRCA120. Future work will be required to reveal the contribution of these genes to glioma 
development and determine if any are acting as “passengers”.  
 
A number of previously reported glioma risk loci were not implicated in our TWAS. The reason may 
be obvious for some loci where the demonstrated functional mechanism is not mediated through a 
cis-regulatory effect on gene expression and therefore is unlikely to be detected by TWAS (e.g. at 
17p13.1 the SNP rs78378222 directly affects TP53 mRNA poly-adenylation21). At other loci such as 
8q24.21 it is less obvious why an association was not detected. It may be that adult brain tissues do 
not represent the best model for these loci, as many genes in this region were not retained for the 
TWAS (genes were only retained if the nested cross-validated correlation between predicted and 
actual levels > 0.10 (R2>1%) and P-value of the correlation test < 0.05). Indeed, we observed a far 
larger number of significant genes for GBM than non-GBM loci. Speculatively, models at earlier 
developmental stages may yield greater insights at these loci, especially if they are influencing 
differentiation down oligodendrocyte/astrocyte lineages. Additionally, other mechanistic effects may 
explain the functional basis of such loci, including methylation and splicing. 
 
Our ability to identify genes significantly associated with glioma risk in this TWAS has inevitably been 
affected by tissue specificity and the sample size of the data set used in the genetic prediction model 
of gene expression. Because of the importance of tissue or cell specific regulators in governing 
development and function, we have sought to analyse the most appropriate tissue-specific model to 
best capture the transcriptional regulatory mechanisms relevant to deciphering glioma 
development. Here we have sought to analyse an appropriate tissue transcriptome to model gene 
expression. We acknowledge that brain tissue does however comprise both neurons and glial cells 
(which include oligodendrocytes, astrocytes, ependymal cells, Schwann cells, microglia, and satellite 
cells). However, in light of abundant shared cis-regulation of expression across multiple brain tissues 
22, by combining data on multiple brain tissues we would expect any model to yield greater power as 
the number of tissues in which a variant is functional increases. Hence we aimed to robustly capture 
genetically regulated genes expression using a large sample size.  
 
In conclusion, this study identified new genes whose predicted expression is associated with glioma 
and serves to illustrate that the TWAS approach can be a useful method of utilising pre-existing 
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GWAS to identify new susceptibility genes. On the basis of the power calculation, our TWAS analysis 
had only 80% power to detect an odds ratio of around 1.1 or 1.2 for GBM or non-GBM glioma risk 
per one standard deviation increase (or decrease) in the expression level of a gene whose cis-
heritability is 60% and 20% respectively. Hence, the application of TWAS based on larger eQTL and 
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Table 1: Genes significantly associated with risk of GBM and Non-GBM glioma. s.d., standard deviation. + 
Specific GBM and non-GBM signals have been reported at 16p13.332. Detailed are the S-MultiXcan P-value for 
association between gene expression and GBM/non-GBM risk and the corresponding Z-scores quantifying this 
relationship (e.g. a positive score indicates increased gene expression increases risk of GBM or non-GBM 
glioma). N and Nindep indicate the total number of single-tissue results used for S-MultiXcan analysis and the 
number of independent components after singular value decomposition, respectively. 
  






















GBM          
20q13.33 ZGPAT 6.85x10-45 3/3 -0.07/14.3 6.69 7.21 YES rs2297440 8.39x10-3 
20q13.33 SLC2A4RG 4.90x10-39 1/1 13.1/13.1 13.1 - YES rs2297440 0.09 
20q13.33 ARFRP1 1.93x10-30 3/3 8.63/11.5 10.5 1.66 YES rs2297440 0.77 
20q13.33 STMN3 4.54x10-27 4/4 -10.9/-0.88 -7.70 4.60 YES rs2297440 0.62 
5p15.33 TERT 5.63x10-26 2/2 -0.43/10.7 5.12 7.86 YES rs10069690 0.63 
20q13.33 GMEB2 3.05x10-16 2/2 -8.26/-8.16 -8.21 0.07 YES rs2297440 0.55 
5p15.33 NKD2 9.46x10-16 6/4 -0.08/4.85 1.49 1.87 YES rs10069690 1.36x10-4 
20q13.33 LIME1 3.60x10-13 2/2 -6.64/5.24 -0.70 8.40 YES rs2297440 5.11x10-3 
16q12.1 HEATR3 3.48x10-10 13/1 4.86/6.73 6.03 0.52 YES rs10852606 0.82 
22q13.1 BAIAP2L2 8.61x10-9 1/1 5.76/5.76 5.76 - YES rs2235573 0.27 
7p11.2 EGFR 1.35x10-8 2/2 -4.70/-4.44 -4.57 0.18 YES rs723527,rs75061358 0.46 
9p21.3 CDKN2B 3.11x10-8 1/1 -5.53/-5.53 -5.53 - YES rs634537 0.38 
22q13.1 SLC16A8 4.88x10-8 3/3 5.45/5.54 5.48 0.05 YES rs2235573 0.84 
20q13.33 HAR1A 2.33x10-7 11/5 -1.48/4.08 0.32 1.48 YES rs2297440 0.90 
20q13.33 OPRL1 6.97x10-7 2/2 -3.99/-2.02 -3.00 1.39 YES rs2297440 0.03 
1p31.3 JAK1 9.29x10-7 4/3 4.11/5.36 4.87 0.56 YES rs12752552 0.16 
20q13.33 PCMTD2 1.07x10-6 5/5 -1.85/3.17 0.91 2.34 YES rs2297440 0.02 
22q13.1 CTA-228A9.3 1.38x10-6 4/4 1.24/5.04 3.80 1.76 YES rs2235573 0.44 
22q13.1 PICK1 1.90x10-6 7/5 3.12/5.78 4.77 1.00 YES rs2235573 0.38 








20q13.33 TCEA2 5.45x10-6 3/3 1.68/5.10 3.55 1.73 YES rs2297440 0.42 
12q13.13 GALNT6 5.68x10-6 10/3 3.10/5.26 4.43 0.68 NO rs3782473 0.82 
          
Non-GBM          
11q23.3 PHLDB1 4.08x10-32 2/2 0.02/12.0 6.02 8.49 YES rs12803321 3.71x10-4 
11q23.3 TREH 1.90x10-16 1/1 8.23/8.23 8.23 - YES rs12803321 1.20x10-4 
20q13.33 ZGPAT 1.18x10-11 3/3 0.04/6.20 3.90 3.36 YES rs2297440 2.17x10-4 
20q13.33 SLC2A4RG 4.44x10-11 1/1 6.59/6.59 6.59 - YES rs2297440 0.09 
11q23.3 RPL5P30 2.09x10-9 2/2 -6.32/-3.99 -5.16 1.65 YES rs12803321 0.55 
5p15.33 TERT 5.09x10-7 2/2 0.50/5.38 2.94 3.45 YES rs10069690 0.96 
20q13.33 LIME1 3.78x10-6 2/2 -3.66/4.24 0.29 5.58 YES rs2297440 3.32x10-3 





Figure 1: Manhattan Plots of gene genomic co-ordinates against –log10(P-value) of TWAS results. 
(a) GBM glioma; (b) Non-GBM glioma. The red line represents the Bonferroni-corrected threshold of 
P≤5.69×10-6. 
 
Figure 2: Regional plot of association results, recombination rates and chromatin state 
segmentation tracks at 12q13.33 in GBM glioma. Plot shows discovery association results of both 
genotyped (triangles) and imputed (circles) SNPs in the GWAS samples and recombination rates. 
−log10 P values (y axes) of the SNPs are shown according to their chromosomal positions (x axes). 
The lead SNP rs3782473 is shown as a large circle. The color intensity of each symbol reflects the 
extent of LD with the top genotyped SNP, white (r2 = 0) through to dark red (r2 = 1.0). Genetic 
recombination rates, estimated using HapMap samples from Utah residents of western and northern 
European ancestry (CEU), are shown with a light blue line. Physical positions are based on NCBI build 
37 of the human genome. Also shown are the relative positions of GENCODE v19 genes mapping to 
the region of association. Below the association plot the location of GALNT6 eSNPs are indicated,  as 
well as the relative positions of GENCODE v19 genes mapping to the region of association and the 
chromatin state segmentation tracks (ChromHMM) for H1 and H9 neural progenitor cells derived 
from the epigenome roadmap project, as per the legend. TSS, transcriptional start sites. 
 
 


